Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study

PURPOSE: To compare testosterone castration levels between patients treated with the gonadotropin-releasing hormone (GnRH) antagonist, degarelix, and GnRH agonist. MATERIALS AND METHODS: Patients with prostate cancer (PCa) of a single outpatient clinic were randomized (2:1) to receive degarelix (gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Mytilekas, Vaios-Konstantinos, Papaefstathiou, Efstathios, Koukourikis, Periklis, Ouzounidis, Xenofon, Kazantzidis, Stavros, Hatzimouratidis, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Urological Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630685/
https://www.ncbi.nlm.nih.gov/pubmed/37932568
http://dx.doi.org/10.4111/icu.20230027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630685/
https://www.ncbi.nlm.nih.gov/pubmed/37932568
http://dx.doi.org/10.4111/icu.20230027

Ejemplares similares